Literature DB >> 28440423

Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF-κB pathway.

Peng Wang1, Jia Cao2, Shihai Liu3, Huazheng Pan4, Xiangping Liu5, Aihua Sui5, Liping Wang5, Ruyong Yao5, Zimin Liu6, Jun Liang7.   

Abstract

Increasing evidence indicates that miR-429 is involved in tumor suppression in various human cancers. however, its role in hepatocellular carcinoma (HCC) remains unclear. In the present study, we found that miR-429 was significantly downregulated in HCC tissue samples and cell lines. Upregulation of miR-429 markedly suppressed proliferation and migration of HCC cells. Moreover, we identified TRAF6 as a direct target of miR-429. Downregulation of TRAF6 partially attenuated the oncogenic effect of anti‑miR-429 on HCC cells. Ectopic expression of miR-429 in HCC cells inhibited TCF-4 activity as well as nuclear accumulation of P65 and expression of the NF-κB targets c-Myc and phosphorylation of TAK1. In a nude xenograft model, miR-429 upregulation significantly decreased HCC growth. In conclusion, by targeting TRAF6, miR-429 is downregulated in HCC and inhibits HCC cell proliferation and motility. Our data suggest that miR-429 may serve as a potential anticancer target for the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28440423     DOI: 10.3892/or.2017.5507

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  Long Non-Coding RNA NEAT1 Promoted Hepatocellular Carcinoma Cell Proliferation and Reduced Apoptosis Through the Regulation of Let-7b-IGF-1R Axis.

Authors:  Qin Liu; Hexian Shi; Jianbo Yang; Ning Jiang
Journal:  Onco Targets Ther       Date:  2019-11-29       Impact factor: 4.147

2.  Long Non-coding RNA XIST Promotes Glioma Tumorigenicity and Angiogenesis by Acting as a Molecular Sponge of miR-429.

Authors:  Zhihua Cheng; Zhenshengnan Li; Ke Ma; Xiaoyu Li; Nan Tian; Jinyue Duan; Xu Xiao; Yi Wang
Journal:  J Cancer       Date:  2017-11-06       Impact factor: 4.207

Review 3.  MicroRNAs as Emerging Regulators of Signaling in the Tumor Microenvironment.

Authors:  Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Cancers (Basel)       Date:  2020-04-08       Impact factor: 6.639

4.  LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.

Authors:  Xia Zhao; Xiaoyou Li; Leilei Zhou; Jie Ni; Wenyue Yan; Rong Ma; Jianzhong Wu; Jifeng Feng; Ping Chen
Journal:  Cancer Sci       Date:  2018-09-02       Impact factor: 6.716

5.  gga-miR-146c Activates TLR6/MyD88/NF-κB Pathway through Targeting MMP16 to Prevent Mycoplasma Gallisepticum (HS Strain) Infection in Chickens.

Authors:  Kang Zhang; Yun Han; Zaiwei Wang; Yabo Zhao; Yali Fu; Xiuli Peng
Journal:  Cells       Date:  2019-05-24       Impact factor: 6.600

6.  PITPNA-AS1 abrogates the inhibition of miR-876-5p on WNT5A to facilitate hepatocellular carcinoma progression.

Authors:  Jianmin Sun; Yubao Zhang; Bing Li; Yuandi Dong; Chengming Sun; Fang Zhang; Li Jin; Dongqin Chen; Wansheng Wang
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

7.  MAPKAPK5-AS1 drives the progression of hepatocellular carcinoma via regulating miR-429/ZEB1 axis.

Authors:  Zongqing Peng; Yexing Wang; Xinhua Ouyang; Qiming Fan
Journal:  BMC Mol Cell Biol       Date:  2022-04-25

Review 8.  MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.

Authors:  Jin'en Wu; Juntao Ding; Jing Yang; Xiaola Guo; Yadong Zheng
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

Review 9.  The miR-200 family: multiple effects on gliomas.

Authors:  Lilei Peng; Jie Fu; Yang Ming
Journal:  Cancer Manag Res       Date:  2018-07-13       Impact factor: 3.989

10.  Down-regulation of microRNA-429 alleviates myocardial injury of rats with coronary heart disease.

Authors:  Qin Yang; Jingrong Li; Hao Zhang; Heping Zuo; Qinglong Zhang; Jinglin Cheng
Journal:  Cell Cycle       Date:  2019-08-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.